Study guide

6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

CAMC Regional Medical Registration Examination Part 1 MCQ

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Overview, Registration Framework & Test Strategy

1.1 Exam Format, Administration & Caribbean Medical Registration Pathways 1.2 Clinical Reasoning & Single-Best-Answer MCQ Test-Taking Strategy 1.3 Regional Epidemiology & Caribbean Healthcare Context

2 Chapter 2: Internal Medicine: Cardiovascular Disorders

2.1 Acute Coronary Syndromes & Myocardial Infarction Management 2.2 Heart Failure Syndromes & Cardiogenic Shock 2.3 Cardiac Arrhythmias, Conduction Blocks & BLS/ACLS Algorithms 2.4 Valvular Heart Disease, Infective Endocarditis & Hypertension

3 Chapter 3: Internal Medicine: Respiratory Medicine & Critical Care

3.1 Asthma & Chronic Obstructive Pulmonary Disease Exacerbations 3.2 Community-Acquired Pneumonia, Hospital-Acquired Pneumonia & Tuberculosis 3.3 Pulmonary Embolism, Pleural Effusion & Pneumothorax

4 Chapter 4: Internal Medicine: Endocrinology & Metabolic Disorders

4.1 Diabetes Mellitus, Diabetic Ketoacidosis & Hyperosmolar Hyperglycaemic State 4.2 Thyroid Disorders: Thyrotoxicosis, Hypothyroidism & Thyroid Storm 4.3 Adrenal Disorders, Pituitary Pathology & Calcium Homeostasis

5 Chapter 5: Internal Medicine: Gastroenterology, Hepatology & Nephrology

5.1 Upper & Lower Gastrointestinal Bleeding: Evaluation & Management 5.2 Cirrhosis, Portal Hypertension & Hepatic Encephalopathy 5.3 Acute Kidney Injury & Chronic Kidney Disease Staging 5.4 Fluid, Electrolyte & Acid-Base Emergencies

6 Chapter 6: Internal Medicine: Neurology, Haematology & Infectious Diseases

6.1 Stroke, Transient Ischaemic Attack & Acute Neurological Deficits 6.2 Sickle Cell Disease, Haemoglobinopathies & Transfusion Medicine 6.3 Dengue Fever, Arboviral Infections & Leptospirosis 6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

7 Chapter 7: General Surgery: Acute Abdomen & Surgical Emergencies

7.1 Acute Abdomen: Peritonitis, Appendicitis & Acute Cholecystitis 7.2 Intestinal Obstruction, Bowel Ischaemia & Perforated Viscus 7.3 Abdominal Wall Hernias: Inguinal, Femoral, Umbilical & Strangulation 7.4 Upper & Lower GI Surgical Pathology & Postoperative Complications

8 Chapter 8: General Surgery: Trauma Resuscitation, Shock & Critical Care

8.1 ATLS Primary Survey & Hemorrhagic Shock Resuscitation 8.2 Thoracic Trauma: Tension Pneumothorax, Hemothorax & Flail Chest 8.3 Abdominal & Pelvic Trauma: FAST Examination & Damage Control Surgery 8.4 Traumatic Brain Injury, Burns & Wound Management

9 Chapter 9: General Surgery: Surgical Subspecialties & Perioperative Care

9.1 Urological Emergencies: Acute Retention, Renal Colic, Torsion & Hematuria 9.2 Musculoskeletal Trauma: Fractures, Dislocations & Compartment Syndrome 9.3 Preoperative Assessment, Surgical Site Infections & Fluid Management 9.4 Otolaryngology: Ear, Nose, Throat & Upper Airway Emergencies 9.5 Clinical Ophthalmology: Acute Red Eye, Glaucoma & Retinal Emergencies

10 Chapter 10: Obstetrics: Antenatal Care, Labor & Complications

10.1 Routine Antenatal Care, Screening & Fetal Assessment 10.2 Hypertensive Disorders of Pregnancy: Pre-eclampsia & Eclampsia 10.3 Antepartum Haemorrhage: Placenta Praevia & Placental Abruption 10.4 Normal Labor, Labor Dystocia & Obstetric Analgesia

11 Chapter 11: Obstetrics & Gynaecology: Postpartum & Pathology

11.1 Postpartum Haemorrhage, Normal Puerperium Physiology & Postpartum Care 11.2 Ectopic Pregnancy, Miscarriage & Gestational Trophoblastic Disease 11.3 Abnormal Uterine Bleeding & Pelvic Inflammatory Disease 11.4 Contraception, Cervical Cancer Screening & Gynaecological Malignancies 11.5 Obstetric & Gynaecological Instruments & Cervical Specimen Collection (PAP Smear Procedures)

12 Chapter 12: Paediatric Medicine: Neonatal Care, Growth & Nutrition

12.1 Neonatal Resuscitation, APGAR Scoring & Prematurity Complications 12.2 Neonatal Jaundice: Physiological, Pathological & Kernicterus 12.3 Growth Monitoring, Developmental Milestones & Failure to Thrive 12.4 Protein-Energy Malnutrition: Kwashiorkor, Marasmus & Nutritional Deficiencies

13 Chapter 13: Paediatric Medicine: Common Illnesses & Emergencies

13.1 Acute Gastroenteritis, Dehydration Assessment & WHO ORS Protocols 13.2 Paediatric Respiratory Illness: Croup, Bronchiolitis & Asthma 13.3 Childhood Infections, Exanthems & Caribbean Immunisation Schedules 13.4 Paediatric Surgical & Medical Emergencies: Intussusception & Febrile Seizures 13.5 Social Paediatrics, Child Protection & Vulnerable Child Health

14 Chapter 14: Psychiatry: Clinical Assessment & Psychopharmacology

14.1 Depressive Disorders, Bipolar Affective Disorder & Suicide Risk Assessment 14.2 Psychosis, Schizophrenia & Acute Delirium vs Dementia 14.3 Anxiety Disorders, Substance Misuse & Psychotropic Side Effects

15 Chapter 15: Community Health, Epidemiology & Preventive Medicine

15.1 Epidemiological Study Designs, Measures of Association & Bias 15.2 Screening Test Performance: Sensitivity, Specificity, PPV & NPV 15.3 Outbreak Investigation, Levels of Prevention & Caribbean NCD Control

16 Chapter 16: Internal Medicine: Rheumatology, Connective Tissue & Dermatology

16.1 Connective Tissue & Collagen Vascular Diseases 16.2 Bone & Joint Diseases: Non-Traumatic Arthropathies & Metabolic Bone Disorders 16.3 Clinical Dermatology: Common, Inflammatory, Bullous, Malignant & Drug-Induced Dermatoses

17 Chapter 17: Anaesthetics, Intensive Care & Clinical Measurements

17.1 Important Anaesthetic Techniques, Airway Management & Methods of Administration 17.2 Clinical Measurements & Intensive Care Monitoring: Cardiac Output, Arterial Blood Gases & Pulmonary Functions 17.3 Acute Pain Management, Multimodal Analgesia & Critical Care Sedation

6.4 HIV/AIDS, Opportunistic Infections & Antimicrobial Stewardship

Key Takeaways Explain This Topic AI

Confirm HIV using the applicable national testing algorithm. Caribbean services use rapid tests and/or laboratory immunoassays; in the CDC laboratory pathway, reactive fourth-generation tests proceed to HIV-1/2 differentiation, with RNA testing for discrepant results or suspected acute infection.

First-line antiretroviral therapy (ART) consists of the integrase strand transfer inhibitor (INSTI) regimen Dolutegravir + Tenofovir disoproxil fumarate + Lamivudine (TLD), which achieves rapid viral suppression with a high genetic barrier to resistance.

Pneumocystis jirovecii pneumonia (PCP, CD4 < 200/uL) presents with subacute exertional dyspnea, dry cough, and marked desaturation out of proportion to exam; treated with high-dose TMP-SMX (21 days) with mandatory adjunctive corticosteroids if PaO2 < 70 mmHg or A-a gradient >= 35 mmHg.

Cryptococcal meningitis (CD4 < 100/uL) requires induction therapy with intravenous amphotericin B deoxycholate plus flucytosine (or high-dose fluconazole) for 14 days, serial therapeutic lumbar punctures to manage elevated opening pressure, and a 4 to 6-week delay of ART initiation to reduce excess mortality and intracranial IRIS risk.

Hospital antimicrobial stewardship enforces early broad empiric therapy for sepsis with review at 48-72 hours for culture-directed narrowing, stopping or continued therapy as appropriate, weight- and GFR-based renal dose adjustment, and restriction of carbapenems to prevent ESBL, MRSA, and carbapenemase-resistant enterobacteriaceae emergence.

Last updated: November 2026

HIV Epidemiology & Diagnostic Algorithms in the Caribbean

The Caribbean region historically has the second highest adult HIV prevalence globally after sub-Saharan Africa. Transmission is predominantly heterosexual, although high burdens persist among key vulnerable populations. Universal Prevention of Mother-to-Child Transmission (PMTCT) programs across the region have successfully eliminated congenital HIV transmission in numerous Caribbean territories through maternal universal screening, triple-antiretroviral prophylaxis during pregnancy, scheduled cesarean delivery for elevated viral loads, and infant formula feeding.

Modern Diagnostic Screening Pathway

4th-Generation Combination Immunoassay: A laboratory screening option; national Caribbean algorithms also use rapid tests. Follow the applicable validated algorithm rather than assuming one regional sequence. This automated chemiluminescent or enzyme immunoassay detects both HIV-1 and HIV-2 antibodies (IgG and IgM) AND the HIV-1 p24 capsid antigen .

Diagnostic Advantage: p24 antigen permits earlier detection than antibody alone. Venous laboratory antigen/antibody tests usually detect infection 18–45 days after exposure, versus 23–90 days for antibody tests. An early negative result may need repeat testing after the applicable window.

Confirmatory Testing: In the CDC laboratory algorithm, a repeatedly reactive 4th-generation screening test is followed by an HIV-1 / HIV-2 antibody differentiation immunoassay (e.g. Geenius assay). This distinguishes HIV-1 from HIV-2, which is critical because HIV-2 is intrinsically resistant to Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) and certain protease inhibitors.

Discrepant or Acute Infection Testing: If the 4th-generation screen is reactive but the differentiation immunoassay is non-reactive or indeterminate, an emergency quantitative HIV-1 RNA PCR viral load is performed. A high viral load (> 100,000 copies/mL) confirms acute primary HIV infection before seroconversion.

Natural History, CD4 Progression & Opportunistic Infections

Following primary infection (which manifests in 50% to 70% of individuals as an acute mononucleosis-like retroviral syndrome), HIV enters a prolonged clinical latency phase lasting 8 to 10 years. Progressive viral replication leads to gradual destruction of CD4+ T-helper lymphocytes. Depletion below specific immunological thresholds predisposes the host to characteristic opportunistic infections (OIs) and malignancies.

Stratification of Opportunistic Conditions by CD4 Count

CD4 Cell Count Opportunistic Infection / Malignancy Clinical Presentation Primary Prophylaxis Regimen

Any CD4 Count Pulmonary Tuberculosis ( M. tuberculosis ) Cough > 2 weeks, hemoptysis, drenching night sweats, weight loss Isoniazid Preventive Therapy (IPT) + Pyridoxine for latent TB

CD4 < 200 / μ L \mu\text{L} μ L (or < 14%) Pneumocystis jirovecii Pneumonia (PCP) Insidious exertional dyspnea, dry cough, severe hypoxia on exertion Trimethoprim-Sulfamethoxazole (TMP-SMX) 1 Double-Strength (DS) tablet daily

CD4 < 100 / μ L \mu\text{L} μ L Cryptococcus neoformans Meningitis Subacute global headache, fever, nausea, subtle meningism, cranial nerve VI palsy CrAg screening; if positive, assess for meningitis and perform LP when feasible. Use pre-emptive fluconazole only when meningitis is excluded

CD4 < 100 / μ L \mu\text{L} μ L Toxoplasma gondii Encephalitis Focal neurological deficits (hemiparesis, aphasia), seizures, ring-enhancing lesions TMP-SMX 1 DS daily if Toxoplasma IgG positive (also covers PCP; PCP prophylaxis has its own indication)

CD4 < 50 / μ L \mu\text{L} μ L Cytomegalovirus (CMV) Retinitis Floaters, painless visual field cuts, perivascular retinal hemorrhages/exudates None routinely; optimize rapid ART initiation

CD4 < 50 / μ L \mu\text{L} μ L Mycobacterium avium Complex (MAC) Disseminated wasting syndrome, high fevers, night sweats, severe hepatosplenomegaly Azithromycin 1200 mg orally once weekly (if not promptly started on ART)

  • Deep Dive: Major Opportunistic Infections
  • 1. Pneumocystis jirovecii Pneumonia (PCP / PJP)

Pathophysiology & Clinical Course: An atypical unicellular fungus that adheres to type I alveolar pneumocytes. Characterized by an insidious, subacute onset over 2 to 4 weeks with dry non-productive cough, low-grade fever, and progressive exertional breathlessness. A classic diagnostic hallmark is exertional oxygen desaturation out of proportion to physical examination (e.g. resting SpO2 94% dropping rapidly to < 85% upon walking across the room).

Investigations:

CXR: Bilateral symmetrical perihilar ground-glass interstitial infiltrates in a 'bat-wing' distribution. Normal in 10% to 15% of early cases.

Serum biomarkers: Elevated lactate dehydrogenase (LDH > 400 U/L) and elevated (1->3)-beta-D-glucan.

Definitive diagnosis: Induced sputum with hypertonic saline or bronchoalveolar lavage (BAL) stained with Gomori methenamine silver (GMS) or direct fluorescent antibody (DFA).

Pharmacotherapy:

First-Line: High-dose intravenous or oral Trimethoprim-Sulfamethoxazole (TMP-SMX) : Trimethoprim 15 to 20 mg/kg/day plus Sulfamethoxazole 75 to 100 mg/kg/day, divided into 3 or 4 doses daily for a total duration of 21 days .

Mandatory Adjunctive Corticosteroids: If arterial blood gas reveals moderate-to-severe hypoxemia—defined as P a O 2 < 70 mmHg PaO_2 < 70\text{ mmHg} P a O 2 ​ < 70 mmHg or Alveolar-arterial (A-a) gradient ≥ 35 mmHg \ge 35\text{ mmHg} ≥ 35 mmHg on room air—start systemic corticosteroids as soon as possible, ideally within 72 hours of starting PCP therapy; do not delay TMP-SMX while arranging steroids.

Steroid Regimen: Oral Prednisone 40 mg BD on days 1–5, 40 mg OD on days 6–10, then 20 mg OD on days 11–21 (or IV methylprednisolone). Steroids prevent fatal acute respiratory failure induced by the inflammatory surge of dying fungal organisms within alveolar spaces.

2. Cryptococcal Meningitis ( Cryptococcus neoformans )

Presentation: Encapsulated budding yeast inhaled into the lungs with subsequent hematogenous dissemination to the meninges. Manifests subacutely over 1 to 3 weeks with progressive global headache, low-grade fevers, malaise, and vomiting. Classical signs of meningeal irritation (nuchal rigidity, Kernig's, Brudzinski's) are absent in over 50% of patients due to profoundly suppressed cell-mediated inflammation.

Diagnostic Workup:

Emergency Lumbar Puncture: Elevated opening pressure (> 200–250 mmH2O); CSF shows lymphocytic pleocytosis (often modest, 20–200 cells/uL), elevated protein, and low glucose.

CSF India Ink Stain: Demonstrates round budding yeasts surrounded by a clear halo (refractile polysaccharide capsule) in 70% to 80% of cases.

Cryptococcal Antigen (CrAg) Lateral Flow Assay: Rapid, highly sensitive (> 98%) and specific diagnostic test performed on both CSF and peripheral serum.

Treatment Protocol:

Induction Phase (14 Days): Intravenous Amphotericin B deoxycholate 0.7 to 1.0 mg/kg/day PLUS oral Flucytosine 100 mg/kg/day (in 4 divided doses). In resource-constrained Caribbean settings where flucytosine is unavailable, high-dose oral Fluconazole 1200 mg daily is substituted alongside Amphotericin B.

Consolidation Phase (8 Weeks): Oral Fluconazole 400 mg to 800 mg daily.

Maintenance / Secondary Prophylaxis: Oral Fluconazole 200 mg daily for at least 1 year from antifungal initiation; stop only when asymptomatic with sustained CD4 >= 100 cells/uL and suppressed HIV RNA on effective ART.

Management of Intracranial Pressure (ICP): Elevated opening pressure is the primary cause of acute mortality. If opening pressure is > 250 mmH2O, perform serial daily therapeutic lumbar punctures removing 20 to 30 mL of CSF until pressure drops < 200 mmH2O or by 50%. Lumbar drains or ventriculoperitoneal shunts are reserved for refractory cases.

3. Cerebral Toxoplasmosis ( Toxoplasma gondii )

Reactivation of latent encysted intracellular protozoa occurring at CD4 < 100 cells/uL.

Presents acutely/subacutely with fever, headache, altered mental status, seizures, and focal neurological deficits (hemiparesis, cranial neuropathies).

Neuroimaging (Contrast CT / MRI): Multiple ring-enhancing lesions with predilection for the basal ganglia, thalamus, and corticomedullary junction, accompanied by surrounding vasogenic edema.

Differentiation from Primary CNS Lymphoma: Lymphoma is typically solitary, periventricular, strongly associated with Epstein-Barr virus (EBV PCR positive in CSF), and shows subependymal spread.

Treatment: Oral Pyrimethamine (200 mg loading, then 50–75 mg daily) PLUS Sulfadiazine (1.0–1.5 g 6-hourly) PLUS Folinic acid (Leucovorin 10–25 mg daily) to prevent pyrimethamine-induced bone marrow megaloblastic anemia. Duration: at least 6 weeks.

4. Cytomegalovirus (CMV) Retinitis

Reactivation of CMV occurring almost exclusively at severe immunodeficiency ( C D 4 < 50 / μ L CD4 < 50/\mu\text{L} C D 4 < 50/ μ L ).

Symptoms: Painless progressive visual impairment, floaters, flashing lights (photopsias), and blind spots (scotomas).

Fundoscopic Appearance: Classic 'pizza-pie' retinopathy (or 'cottage cheese and ketchup'): dense, confluent, yellow-white perivascular retinal infiltrates and necrotizing retinitis surrounded by extensive retinal hemorrhages and vasculitis.

Treatment: Intravenous Ganciclovir (5 mg/kg 12-hourly for 14 to 21 days) or oral Valganciclovir 900 mg BD for 21 days , followed by maintenance therapy until immune reconstitution occurs.

  • Antiretroviral Therapy (ART) & Timing Principles
  • Modern First-Line Regimen: The TLD Triad

Across the Caribbean, the World Health Organization (WHO) recommended first-line regimen for adults and adolescents is the fixed-dose combination TLD taken orally once daily:

T — Tenofovir Disoproxil Fumarate (TDF, 300 mg): Nucleotide Reverse Transcriptase Inhibitor (NRTI). High efficacy; requires baseline and periodic monitoring of serum creatinine and urinalysis due to risks of proximal renal tubulopathy (Fanconi-like syndrome) and bone mineral density loss. (Tenofovir Alafenamide [TAF] is used in renal impairment).

L — Lamivudine (3TC, 300 mg): Nucleoside Reverse Transcriptase Inhibitor (NRTI). Well tolerated, minimal toxicity; active against Hepatitis B virus.

D — Dolutegravir (DTG, 50 mg): An INSTI with rapid suppression and a high resistance barrier . With rifampicin, add DTG 50 mg 12 hours after daily TLD; continue the extra dose for 2 weeks after rifampicin ends.

Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS is an exaggerated pathological inflammatory reaction against dead or viable microbial antigens occurring within weeks to months of initiating effective ART, triggered by the rapid restoration of pathogen-specific cell-mediated immune responses. It manifests in two forms:

Paradoxical IRIS: Worsening of a treated, recognized opportunistic infection despite microbiological cure.

Unmasking IRIS: Explosive presentation of a previously subclinical, occult infection.

The Timing Dilemma: When to Start ART in Opportunistic Infections

General Rule for Most OIs (PCP, Bacterial Pneumonia, Diarrheal Illnesses): Initiate ART within 2 weeks of starting OI therapy ('immediate ART'). Delaying ART increases the risk of AIDS progression and mortality.

CRITICAL EXCEPTION 1: Cryptococcal Meningitis:

Generally defer ART initiation for 4 to 6 weeks after starting antifungal induction therapy, until CSF fungal clearance is documented and intracranial pressure is controlled.

Rationale: The COAT trial found higher 26-week mortality with ART started at 1–2 weeks than with deferred initiation around 5 weeks. Intracranial inflammatory deterioration is a major concern; early ART should not be used to accelerate recovery from cryptococcal meningitis.

CRITICAL EXCEPTION 2: Tuberculous Meningitis:

ART must be delayed for 4 to 8 weeks after starting antitubercular therapy (HRZE) and high-dose dexamethasone, similarly to prevent fatal cerebral IRIS. (In pulmonary non-CNS TB with CD4 < 50, start ART within 2 weeks; with CD4 >= 50, start within 8 weeks).

Hospital Antimicrobial Stewardship Principles

Antimicrobial resistance (AMR) represents an existential threat to healthcare delivery in the Caribbean. Overuse of broad-spectrum antimicrobials fuels the emergence of Multidrug-Resistant Organisms (MDROs), notably Extended-Spectrum Beta-Lactamase (ESBL) producing Enterobacteriaceae , Carbapenem-Resistant Enterobacteriaceae (CRE), Methicillin-Resistant Staphylococcus aureus (MRSA), and Vancomycin-Resistant Enterococci (VRE).

Core Tenets of Clinical Stewardship

Diagnostic Stewardship: Obtain appropriate high-volume blood cultures (at least two sets from separate venipuncture sites) and target-site cultures (urine, sputum, pleural fluid, CSF) BEFORE administering antimicrobials, without causing unreasonable delays in patients with septic shock.

The 48- to 72-Hour Antimicrobial 'Time-Out': When microbiological culture and susceptibility results return at 48–72 hours, clinicians must reassess therapy:

De-escalation: Switch from broad empiric regimens (e.g. piperacillin-tazobactam or meropenem) to the narrowest-spectrum agent directed against the identified isolate (e.g. de-escalating to high-dose ampicillin or ceftriaxone for fully susceptible pneumococcus).

Discontinuation: Stop empiric MRSA coverage when cultures, infection site, local epidemiology and clinical response make MRSA unlikely. A negative nasal PCR supports de-escalation in appropriate pneumonia settings; it does not exclude every MRSA infection. Stop antibiotics when an infectious cause is ruled out.

Early Intravenous-to-Oral (IV-to-PO) Switch: Review at 48–72 hours and switch when the patient is improving, GI absorption is adequate and an effective oral regimen suits the infection. High-bioavailability options include ciprofloxacin, linezolid, fluconazole, metronidazole and doxycycline. CNS, endovascular and other deep infections require syndrome-specific plans.

Therapeutic Drug Monitoring (TDM) & Renal Dosing: Calculate Cockcroft-Gault creatinine clearance daily for renally excreted toxic drugs (vancomycin, aminoglycosides, colistin). For serious MRSA infections, use AUC-guided vancomycin dosing (AUC24 400–600 mg·h/L, assuming MIC 1 mg/L) and monitor renal function; trough-only targeting of 15–20 mcg/mL is no longer recommended because of nephrotoxicity.

Loading diagram... Antiretroviral Therapy Initiation & Opportunistic Infection Sequencing Pathway